{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:01:44Z","timestamp":1787882504889,"version":"build-2784847793"},"reference-count":86,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The coronavirus disease of 2019 (COVID-19) pandemic has posed a serious threat to humanity and is considered a global health emergency. Antimalarial drugs (ADs) have been used in the treatment of immuno-inflammatory arthritis (IIA) and coronavirus infection (COVID-19). The aim of this review is to analyze the current knowledge about the immunomodulatory and antiviral mechanisms of action, characteristics of use, and side effects of antimalarial drugs. Material and Methods: A literature search was carried out using PubMed, MEDLINE, SCOPUS, and Google Scholar databases. The inclusion criteria were the results of randomized and cohort studies, meta-analyses, systematic reviews, and original full-text manuscripts in the English language containing statistically confirmed conclusions. The exclusion criteria were summary reports, newspaper articles, and personal messages. Qualitative methods were used for theoretical knowledge on antimalarial drug usage in AIRDs and SARS-CoV-2 such as a summarization of the literature and a comparison of the treatment methods. Results: The ADs were considered a \u201ccandidate\u201d for the therapy of a new coronavirus infection due to mechanisms of antiviral activity, such as interactions with endocytic pathways, the prevention of glycosylation of the ACE2 receptors, blocking sialic acid receptors, and reducing the manifestations of cytokine storms. The majority of clinical trials suggest no role of antimalarial drugs in COVID-19 treatment or prevention. These circumstances do not allow for their use in the treatment and prevention of COVID-19. Conclusions: The mechanisms of hydroxychloroquine are related to potential cardiotoxic manifestations and demonstrate potential adverse effects when used for COVID-19. Furthermore, the need for high doses in the treatment of viral infections increases the likelihood of gastrointestinal side effects, the prolongation of QT, and retinopathy. Large randomized clinical trials (RCTs) have refuted the fact that there is a positive effect on the course and results of COVID-19.<\/jats:p>","DOI":"10.3390\/medicina60071171","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T13:12:57Z","timestamp":1721394777000},"page":"1171","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antimalarial Drugs at the Intersection of SARS-CoV-2 and Rheumatic Diseases: What Are the Potential Opportunities?"],"prefix":"10.3390","volume":"60","author":[{"given":"Saule","family":"Abisheva","sequence":"first","affiliation":[{"name":"Department of Family Medicine \u21161, NJSC \u201cAstana Medical University\u201d, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-8720","authenticated-orcid":false,"given":"Kristina","family":"Rutskaya-Moroshan","sequence":"additional","affiliation":[{"name":"Department of Family Medicine \u21161, NJSC \u201cAstana Medical University\u201d, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulnaz","family":"Nuranova","sequence":"additional","affiliation":[{"name":"Department of Children\u2019s Diseases with Courses in Pulmonology and Nephrology, NJSC \u201cAstana Medical University\u201d, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tansholpan","family":"Batyrkhan","sequence":"additional","affiliation":[{"name":"Department of Family Medicine \u21161, NJSC \u201cAstana Medical University\u201d, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anilim","family":"Abisheva","sequence":"additional","affiliation":[{"name":"Department of Family Medicine \u21161, NJSC \u201cAstana Medical University\u201d, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.14412\/1996-7012-2022-5-82-87","article-title":"Shared Features of Pathogenetic Aspects, Autoimmunity and Pharmacotherapy in Coronavirus Infection (COVID-19) and Immunoinflammatory Rheumatic Diseases","volume":"16","author":"Abisheva","year":"2022","journal-title":"Mod. Rheumatol. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.7150\/ijbs.59272","article-title":"Cytokine storm in COVID-19: From viral infection to immune responses, diagnosis and therapy","volume":"18","author":"Jiang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","article-title":"Drug Repurposing Approach to Fight COVID-19","volume":"72","author":"Singh","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Schlegel, M., and Bachmann, S. (2024). Influence of the COVID-19 Pandemic on Medical Management and on Healthcare Delivery of Immune-Mediated Rheumatic and Musculoskeletal Diseases during the First Pandemic Period February to July 2020: A Systematic Review. Medicina, 60.","DOI":"10.3390\/medicina60040596"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2213-2600(20)30216-2","article-title":"COVID-19 Cytokine Storm: The Interplay between Inflammation and Coagulation","volume":"8","author":"Jose","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J. Heart Lung Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1177\/0961203396005001031","article-title":"Anti-Malarial Drugs: Possible Mechanisms of Action in Autoimmune Disease and Prospects for Drug Development","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1177\/0961203396005001021","article-title":"The history of antimalarials","volume":"5","author":"Wallace","year":"1996","journal-title":"Lupus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: Implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Browning, D.J. (2014). Pharmacology of Chloroquine and Hydroxychloroquine. Hydroxychloroquine and Chloroquine Retinopathy, Springer.","DOI":"10.1007\/978-1-4939-0597-3"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1177\/0961203312450084","article-title":"Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: A longitudinal evaluation of the lipid-lowering effect","volume":"21","author":"Cairoli","year":"2012","journal-title":"Lupus"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1191\/0961203302lu147rr","article-title":"Antimalarials in cutaneous lupus erythematosus: Mechanisms of therapeutic benefit","volume":"11","author":"Wozniacka","year":"2002","journal-title":"Lupus"},{"key":"ref_15","first-page":"S297","article-title":"Arterial thrombotic events (TE) in SLE: The Baltimore Lupus Cohort study","volume":"37","author":"Petri","year":"1994","journal-title":"Arthr. Rheum."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of Antimalarials on Thrombosis and Survival in Patients with Systemic Lupus Erythematosus","volume":"15","author":"Egurbide","year":"2006","journal-title":"Lupus"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR Points to Consider for Use of Antirheumatic Drugs before Pregnancy, and during Pregnancy and Lactation","volume":"75","author":"Hoeltzenbein","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/rheumatology\/kev404","article-title":"BSR and BHPR Guideline on Prescribing Drugs in Pregnancy and Breastfeeding-Part I: Standard and Biologic Disease Modifying Anti-Rheumatic Drugs and Corticosteroids","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR Recommendations for Women\u2019s Health and the Management of Family Planning, Assisted Reproduction, Pregnancy and Menopause in Patients with Systemic Lupus Erythematosus and\/or Antiphospholipid Syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/acr.24130","article-title":"2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Care Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/art.38262","article-title":"Brief Report: Risk of Adverse Fetal Outcomes Associated with Immunosuppressive Medications for Chronic Immune-Mediated Diseases in Pregnancy","volume":"66","author":"Cooper","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.reprotox.2013.04.005","article-title":"Pregnancy Outcome Following in Utero Exposure to Hydroxychloroquine: A Prospective Comparative Observational Study","volume":"39","author":"Blyakhman","year":"2013","journal-title":"Reprod. Toxicol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e000651","DOI":"10.1136\/lupus-2021-000651","article-title":"Hydroxychloroquine in the Pregnancies of Women with Lupus: A Meta-Analysis of Individual Participant Data","volume":"9","author":"Clowse","year":"2022","journal-title":"Lupus Sci. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jbspin.2018.03.006","article-title":"F\u00e9d\u00e9ration Hospitalo-Universitaire Acronim Hydroxychloroquine for the Prevention of Fetal Growth Restriction and Prematurity in Lupus Pregnancy: A Systematic Review and Meta-Analysis","volume":"85","author":"Guillotin","year":"2018","journal-title":"Jt. Bone Spine"},{"key":"ref_26","first-page":"855","article-title":"Effect of Pregnancy on Disease Flares in Patients with Systemic Lupus Erythematosus","volume":"77","author":"Eudy","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1177\/09612033211007199","article-title":"Hydroxychloroquine Prophylaxis for Preeclampsia, Hypertension and Prematurity in Pregnant Patients with Systemic Lupus Erythematosus: A Meta-Analysis","volume":"30","author":"Duan","year":"2021","journal-title":"Lupus"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/rheumatology\/kex191","article-title":"Prenatal Exposure to Antimalarials Decreases the Risk of Cardiac but Not Non-Cardiac Neonatal Lupus: A Single-Centre Cohort Study","volume":"56","author":"Barsalou","year":"2017","journal-title":"Rheumatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/CIRCULATIONAHA.111.089268","article-title":"Maternal Use of Hydroxychloroquine Is Associated with a Reduced Risk of Recurrent Anti-SSA\/Ro-Antibody-Associated Cardiac Manifestations of Neonatal Lupus","volume":"126","author":"Izmirly","year":"2012","journal-title":"Circulation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2009.119263","article-title":"Evaluation of the Risk of Anti-SSA\/Ro-SSB\/La Antibody-Associated Cardiac Manifestations of Neonatal Lupus in Fetuses of Mothers with Systemic Lupus Erythematosus Exposed to Hydroxychloroquine","volume":"69","author":"Izmirly","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12026-016-8888-5","article-title":"Obstetric and Perinatal Outcome in Anti-Ro\/SSA-Positive Pregnant Women: A Prospective Cohort Study","volume":"65","author":"Bartha","year":"2017","journal-title":"Immunol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jacc.2020.05.045","article-title":"Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA\/Ro-Positive Mothers","volume":"76","author":"Izmirly","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/0961203312437270","article-title":"Effect of Hydroxychloroquine Treatment on Pro-Inflammatory Cytokines and Disease Activity in SLE Patients: Data from LUMINA (LXXV), a Multiethnic US Cohort","volume":"21","author":"Willis","year":"2012","journal-title":"Lupus"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11926-010-0141-y","article-title":"Use of Hydroxychloroquine to Prevent Thrombosis in Systemic Lupus Erythematosus and in Antiphospholipid Antibody-Positive Patients","volume":"13","author":"Petri","year":"2011","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical Efficacy and Side Effects of Antimalarials in Systemic Lupus Erythematosus: A Systematic Review","volume":"69","author":"Khamashta","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ncprheum0292","article-title":"Mode of Action of Hydroxychloroquine in RA-Evidence of an Inhibitory Effect on Toll-like Receptor Signaling","volume":"2","author":"Kyburz","year":"2006","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/art.22159","article-title":"Hydroxychloroquine in Lupus Pregnancy","volume":"54","author":"Clowse","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0961203307078579","article-title":"Hydroxychloroquine Sulfate Treatment Is Associated with Later Onset of Systemic Lupus Erythematosus","volume":"16","author":"James","year":"2007","journal-title":"Lupus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/acr.22968","article-title":"Treatment guidelines for rheumatologic manifestations of Sjogren\u2019s syndrome: Use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain","volume":"69","author":"Carsons","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Price, E.J., Benjamin, S., Bombardieri, M., Bowman, S., Carty, S., Ciurtin, C., Crampton, B., Dawson, A., Fisher, B.A., and Giles, I. (2024). British Society for Rheumatology guideline on management of adult and juvenile onset Sj\u00f6gren disease. Rheumatology, keae152.","DOI":"10.1093\/rheumatology\/keae152"},{"key":"ref_41","first-page":"229","article-title":"Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjogren\u2019s syndrome","volume":"11","author":"Mumcu","year":"2013","journal-title":"Oral. Health Prev. Dent."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00296-010-1415-4","article-title":"Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren\u2019s syndrome","volume":"31","author":"Yavuz","year":"2011","journal-title":"Rheumatol. Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1529-8019.2007.00131.x","article-title":"New Concepts in Antimalarial Use and Mode of Action in Dermatology","volume":"20","author":"Kalia","year":"2007","journal-title":"Dermatol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2165\/00003495-200868100-00003","article-title":"Evidence-Based Therapy for Cutaneous Sarcoidosis","volume":"68","author":"Doherty","year":"2008","journal-title":"Drugs"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/ndt\/gft442","article-title":"Treatment of Renal Sarcoidosis: Is There a Guideline? Overview of the Different Treatment Options","volume":"29","author":"Hilderson","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/archderm.141.7.855","article-title":"Combination antimalarials in the treatment of cutaneous dermatomyositis. A retrospective study","volume":"141","author":"Ang","year":"2005","journal-title":"Arch. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: An old drug against today\u2019s diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.antiviral.2007.10.011","article-title":"Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: Involvement of p38 MAPK and ERK","volume":"77","author":"Kono","year":"2008","journal-title":"Antivir. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1473-3099(05)70026-8","article-title":"Avian influenza and sialic acid receptors: More than meets the eye?","volume":"5","author":"Olofsson","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/cr.2008.15","article-title":"SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Burkard, C., Verheije, M.H., Wicht, O., van Kasteren, S.I., van Kuppeveld, F.J., Haagmans, B.L., Pelkmans, L., Rottier, P.J., Bosch, B.J., and de Haan, C.A. (2014). Coronavirus cell entry occurs through the endo-\/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004502"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel Coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.virol.2011.02.020","article-title":"Different Host Cell Proteases Activate the SARS-Coronavirus Spike-Protein for Cell\u2013Cell and Virus\u2013Cell Fusion","volume":"413","author":"Simmons","year":"2011","journal-title":"Virology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine Is a Potent Inhibitor of SARS Coronavirus Infection and Spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/jmv.26139","article-title":"Increasing Host Cellular Receptor-Angiotensin-Converting Enzyme 2 Expression by Coronavirus May Facilitate 2019-nCoV (or SARS-CoV-2) Infection","volume":"92","author":"Zhuang","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/glycob\/cwab032","article-title":"The role of cell surface sialic acids for SARS-CoV-2 infection","volume":"31","author":"Sun","year":"2021","journal-title":"Glycobiology"},{"key":"ref_58","unstructured":"De Gonzague, D.M.L., Rabetafika, D.R.R.T., Rindra, D.R., Mihaja, R.N., Cyris, D.H.J., and L\u00e9a, P.R. (2020). Beware of 2019-nCoV Transmission through the Ocular Surface. EC Opthalmology Spec Issue, ECronicon."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Wang, P.H., and Cheng, Y. (2020). Increasing host cellular receptor\u2014Angiotensin-converting enzyme 2 (ACE2) expression by coronavirus may facilitate 2019-nCoV infection. bioRxiv.","DOI":"10.1101\/2020.02.24.963348"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkaa114","article-title":"COVID-19: A recommendation to examine the effect of hydroxychloroquine in preventing infection and progression","volume":"75","author":"Zhou","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s00213-019-5166-y","article-title":"Cannabinoid receptor 2 activation mitigates lipopolysaccharide-induced neuroinflammation and sickness behavior in mice","volume":"236","author":"Sahu","year":"2019","journal-title":"Psychopharmacology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/art.40559","article-title":"Inhibition of Cyclic GMP-AMP Synthase Using a Novel Antimalarial Drug Derivative in Trex1-Deficient Mice","volume":"70","author":"An","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"101738","DOI":"10.1016\/j.tmaid.2020.101738","article-title":"Early Treatment of COVID-19 Patients with Hydroxychloroquine and Azithromycin: A Retrospective Analysis of 1061 Cases in Marseille, France","volume":"35","author":"Million","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ni.1656","article-title":"Priming for T Helper Type 2 Differentiation by Interleukin 2-Mediated Induction of Interleukin 4 Receptor Alpha-Chain Expression","volume":"9","author":"Liao","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1111\/ajt.15935","article-title":"COVID-19 Pneumonia in a Kidney Transplant Recipient Successfully Treated with Tocilizumab and Hydroxychloroquine","volume":"20","author":"Fontana","year":"2020","journal-title":"Am. J. Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s11739-020-02505-x","article-title":"The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients","volume":"15","author":"Ayerbe","year":"2020","journal-title":"Intern. Emerg. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijid.2020.06.099","article-title":"COVID-19 Task Force. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19","volume":"97","author":"Arshad","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(20)31862-6","article-title":"Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): A randomised linical trial","volume":"396","author":"Furtado","year":"2020","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate COVID-19","volume":"383","author":"Cavalcanti","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with COVID-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with inhospital mortality in patients with COVID-19 in New York state","volume":"323","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group, Horby, P., Mafham, M., Linsell, L., Bell, J.L., Staplin, N., Emberson, J.R., Wiselka, M., Ustianowski, A., and Elmahi, E. (2020). Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19. N. Engl. J. Med., 383, 2030\u20132040.","DOI":"10.1056\/NEJMoa2022926"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"WHO Solidarity Trial Consortium, Pan, H., Peto, R., Henao-Restrepo, A.-M., Preziosi, M.-P., Sathiyamoorthy, V., Abdool Karim, Q., Alejandria, M.M., Hern\u00e1ndez Garc\u00eda, C., and Kieny, M.-P. (2021). Repurposed Antiviral Drugs for COVID-19\u2014Interim WHO Solidarity Trial Results. N. Engl. J. Med., 384, 497\u2013511.","DOI":"10.1056\/NEJMoa2023184"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Yu, B., Li, C., Chen, P., Zhou, N., Wang, L., Li, J., Jiang, H., and Wang, D.W. (2020). Hydroxychloroquine Application Is Associated with a Decreased Mortality in Critically Ill Patients with COVID-19. medRxiv.","DOI":"10.1101\/2020.04.27.20073379"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"623","DOI":"10.7326\/M20-4207","article-title":"Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial","volume":"173","author":"Skipper","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.hrthm.2020.05.008","article-title":"QT Prolongation, Torsades de Pointes, and Sudden Death with Short Courses of Chloroquine or Hydroxychloroquine as Used in COVID-19: A Systematic Review","volume":"17","author":"Jankelson","year":"2020","journal-title":"Heart Rhythm."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A Living WHO Guideline on Drugs for COVID-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"n526","DOI":"10.1136\/bmj.n526","article-title":"A living WHO guideline on drugs to prevent COVID-19","volume":"372","author":"Lamontagne","year":"2021","journal-title":"BMJ"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.4103\/jfmpc.jfmpc_1961_20","article-title":"Hydroxychloroquine: A Review of Its Safety and Efficacy in COVID-19","volume":"10","author":"Karia","year":"2021","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"White, N.J., Watson, J.A., Hoglund, R.M., Chan, X.H.S., Cheah, P.Y., and Tarning, J. (2020). COVID-19 Prevention and Treatment: A Critical Analysis of Chloroquine and Hydroxychloroquine Clinical Pharmacology. PLoS Med., 17.","DOI":"10.1371\/journal.pmed.1003252"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/eye.2016.298","article-title":"Hydroxychloroquine Retinopathy","volume":"31","author":"Yusuf","year":"2017","journal-title":"Eye"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamadermatol.2013.709","article-title":"Hydroxychloroquine-Induced Pigmentation in Patients with Systemic Lupus Erythematosus: A Case-Control Study","volume":"149","author":"Jallouli","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/RHU.0000000000000417","article-title":"Hydroxychloroquine-Induced Erythema Multiforme","volume":"23","author":"Assalie","year":"2017","journal-title":"J. Clin. Rheumatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1096\/fj.202000919","article-title":"Rethinking the Role of Hydroxychloroquine in the Treatment of COVID-19","volume":"34","author":"Meyerowitz","year":"2020","journal-title":"FASEB J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"ofaa130","DOI":"10.1093\/ofid\/ofaa130","article-title":"Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)","volume":"7","author":"Pastick","year":"2020","journal-title":"Open Forum Infect. Dis."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/7\/1171\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:19:44Z","timestamp":1760109584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/7\/1171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":86,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["medicina60071171"],"URL":"https:\/\/doi.org\/10.3390\/medicina60071171","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,19]]}}}